Ohtuvayre (Ensifentrine) - Is there a generic version of Ensifentrine?

Ohtuvayre (Ensifentrine) - Ensifentrine's primary indication is the treatment of chronic obstructive pulmonary disease (COPD), a chronic disease characterized by airway obstruction and difficulty breathing. As global air pollution intensifies and smoking rates increase, the incidence of COPD is increasing day by day, becoming a health problem that seriously affects people's quality of life. Exefentine can effectively improve patients' airway patency and inflammatory response through its unique dual phosphodiesterase inhibition mechanism, and is therefore used to relieve the symptoms of COPD patients and improve their quality of life.

Although Exefantine has performed well in the international market, there are currently no generic drugs for sale in domestic or foreign markets. The original research versionOhtuvayre has not yet been officially launched in China, which has brought certain inconvenience to patients who need to use the drug. Due to the lack of locally produced generic drugs, patients often have to obtain the drug through overseas channels. This situation has forced some patients who urgently need the drug to face higher drug purchase costs and logistics risks.

According to market information,Ohtuvayre has been approved and marketed in some overseas regions such as the United States. The common specification is 3mg/2.5mL (60 doses). However, in China, the entry of Ohtuvayre still faces challenges due to the complexity of the drug approval process and market supervision. Currently, some patients choose to purchase through specific pharmacies or international drug purchase platforms. However, this method is not only expensive, but also involves certain legal and compliance risks.

In terms of price,Ohtuvayre is sold in pharmacies in Hong Kong, China for about 44,500 Hong Kong dollars, which is equivalent to more than 40,000 yuan in RMB. This price is undoubtedly a significant expense for most patients, and coupled with the possible price fluctuations caused by exchange rate fluctuations, many patients feel pressured by the financial burden. Therefore, the high cost of exefantine and its unavailability in the domestic market make patients face greater challenges during treatment.

Reference materials:https://go.drugbank.com/drugs/DB16157